secwatch.observer — SEC 8-K summary
======================================

Issuer:     TriSalus Life Sciences, Inc. (TLSI)
CIK:        0001826667
Form:       8-K
Filed at:   2024-03-12T23:59:59+00:00
Accession:  0001104659-24-033157
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

TriSalus reports preliminary Q4 revenue $5.7M (+77% YoY) and FY23 revenue $18.5M (+49% YoY)
--------------------------------------------------------------------------------

- Preliminary Q4 2023 revenue $5.7M (up 77% vs Q4 2022); full-year 2023 revenue $18.5M (up 49% vs 2022).
- Gross margin improved to ~90% in Q4 2023 and ~86% for FY2023, vs 75% and 82% a year ago.
- Cash and equivalents $11.8M as of Dec 31, 2023; expects liquidity to fund operations into Q2 2024.
- Revenue entirely from TriNav Infusion System; final audited financials not yet released.
- Preliminary estimates are unaudited and subject to change; auditor has not performed any procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/0001104659-24-033157-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826667/000110465924033157/tm248546d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-033157

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer